RT Journal Article
SR Electronic
T1 DNA methylation signatures of C-reactive protein associations with structural neuroimaging measures and major depressive disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.12.20173567
DO 10.1101/2020.08.12.20173567
A1 Claire Green
A1 Xueyi Shen
A1 Anna J. Stevenson
A1 Eleanor L.S. Conole
A1 Mathew A. Harris
A1 Miruna C. Barbu
A1 Emma L. Hawkins
A1 Mark J. Adams
A1 Stephen M. Lawrie
A1 Kathryn L. Evans
A1 Rosie M. Walker
A1 Stewart W. Morris
A1 David J. Porteous
A1 Joanna M. Wardlaw
A1 J Douglas Steele
A1 Gordon D. Waiter
A1 Anca-Larisa Sandu
A1 Archie Campbell
A1 Riccardo E. Marioni
A1 Simon R. Cox
A1 Jonathan Cavanagh
A1 Andrew M. McIntosh
A1 Heather C. Whalley
YR 2020
UL http://medrxiv.org/content/early/2020/08/17/2020.08.12.20173567.abstract
AB Background Inflammatory processes are implicated in the aetiology of Major Depressive Disorder (MDD); however, the relationship between peripheral inflammation, brain structure and depression remains unclear. This study investigates associations between depression, structural neuroimaging measures and two measures of inflammation: serum-based C-reactive protein (CRP) and a methylation-based score for CRP (DNAm CRP) in a large community-based sample.Methods Serum CRP and DNAm CRP were assessed for participants in Generation Scotland (NMDD cases = 240, Ncontrols = 558) alongside structural brain scans (T1 and diffusion MRI). Linear regression was used to investigate associations between (i) both CRP measures and depressive symptoms, (ii) both CRP measures and structural imaging variables and (iii) inflammation x MDD interaction effects (for both CRP measures) with imaging measures.Results Increased serum CRP was significantly associated with overall MDD symptom severity and specifically with somatic symptoms-general interest (β= 0.145, PFDR = 6×10-4) and energy levels (β= 0.101, PFDR = 0.027) and also reduced entorhinal cortex thickness (β= – 0.095, PFDR = 0.037). DNAm CRP was significantly associated with reduced global grey matter/cortical volume and reduced integrity of 16 white matter tracts and showed larger effect sizes (βaverage = −0.15) compared to serum CRP across all measures (βaverage = 0.01).Conclusions Acute measures of CRP were related to current depression symptoms, specifically somatic symptoms, whereas methylation signatures of inflammation demonstrated greater differences in global and regional brain structure. This study highlights the utility of combining serological and methylation markers to study chronic inflammation effects on the brain in psychiatric disorders.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGeneration Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006] and is currently supported by the Wellcome Trust [216767/Z/19/Z]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award STratifying Resilience and Depression Longitudinally (STRADL) Reference 104036/Z/14/Z). CG is supported by The Medical Research Council and The University of Edinburgh through the Precision Medicine Doctoral Training program. SRC is supported by the UK Medical Research Council [MR/R024065/1] and a National Institutes of Health (NIH) research grant R01AG054628.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for STRADL was formally obtained from the NHS Tayside committee on research (reference 14/SS/0039).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAccess to and use of GS and STRADL data must be approved by the GS Access Committee under the terms of consent. Full details of the application process can be found at www.generationscotland.org